Sign in Membership
Kelly Ke

Kelly Ke

Jun 07, 2023

Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities

In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
May 24, 2023

Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations

Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
May 10, 2023

How China’s Provider Payment Reform Will Impact Key Healthcare Stakeholders

Our last article discussed the context behind the DRG/DIP payment reform and how China has adopted this dual-track payment
May 03, 2023

Understanding China's Dual-Track DRG DIP Provider Payment Reform

China has undergone a significant transformation in its healthcare system in recent years. One central area of reform has been
Apr 26, 2023

Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance

In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
Apr 19, 2023

Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")

In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
Apr 12, 2023

Access Pathway for Innovative Medicines in China: Basic Social Medical Insurance

To understand the access pathways for innovative medicines in China, we have to follow the money. Three layers in China’